Compare YieldMax TSLA Option Income Strategy ETF (TSLY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax TSLA Option Income Strategy ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? YieldMax TSLA Option Income Strategy ETF trades at $21.17 (market cap $676.85M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 7.4× YieldMax TSLA Option Income Strategy ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax TSLA Option Income Strategy ETF for 45 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TSLY | TVTX | |
|---|---|---|
Market Cap | $676.85M | $5.02B |
Volume | 384,817 | 2,060,842 |
Sector | Income / Options Overlay | Health |
52-Week High | $43.35 | $67.52 |
52-Week Low | $20.49 | $26.79 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TSLY trades at $22.11, down 0.58% with a bearish technical signal from moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.26, though recent news highlights concerns about underperformance relative to Tesla's stock gains. Technical indicators show neutral oscillators with key support at $22 and resistance at $23.
The outlook remains cautious as TSLY faces structural challenges capturing Tesla's upside while providing income. Investors should weigh the high dividend yield against potential capital erosion during Tesla rallies. Key risks include volatility regime changes and the ETF's option strategy limitations in strong bull markets.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
